Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models-Reference-Cited by-同舟云学术

Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models

Published:2012-04-02 Issue:4 Volume:122 Page:1541-1552
ISSN:0021-9738
Container-title:Journal of Clinical Investigation
language:en
Short-container-title:J. Clin. Invest.

Author:

Ma Cynthia X.,Cai Shirong,Li Shunqiang,Ryan Christine E.,Guo Zhanfang,Schaiff W. Timothy,Lin Li,Hoog Jeremy,Goiffon Reece J.,Prat Aleix,Aft Rebecca L.,Ellis Matthew J.,Piwnica-Worms Helen

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Reference54 articles.

1. Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study

2. A Maternal Form of the Phosphatase Cdc25A Regulates Early Embryonic Cell Cycles in Xenopus laevis

3. Chk1 is activated transiently and targets Cdc25A for degradation at the Xenopus midblastula transition

4. Chk1 regulates the S phase checkpoint by coupling the physiological turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A

5. Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints

Cited by 187 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inhibition of GPX4 Induces the Death of p53-Mutant Triple-Negative Breast Cancer Cells;2024-09-02

2. The treatment landscape of triple-negative breast cancer;Medical Oncology;2024-08-29

3. Polθ: emerging synthetic lethal partner in homologous recombination-deficient tumors;Cancer Gene Therapy;2024-08-09

4. Pan-cancer proteogenomics expands the landscape of therapeutic targets;Cell;2024-08

5. The thioredoxin system determines CHK1 inhibitor sensitivity via redox-mediated regulation of ribonucleotide reductase activity;Nature Communications;2024-05-31